Promis Neurosciences INC 8-K filings

ProMIS Neurosciences announced positive blinded interim safety and biomarker data for its Alzheimer's drug candidate, PMN310, showing no ARIA-E and encouraging biomarker trends.

ProMIS Neurosciences announced its first quarter 2026 financial results, highlighting the closure of a significant financing round and progress in its Phase 1b Alzheimer's disease trial.

ProMIS Neurosciences announced its full year 2025 financial results and provided a corporate update, highlighting significant progress in its Alzheimer's disease clinical trial and securing substantial financing.

ProMIS Neurosciences Inc. announced a private placement financing of up to $175 million, extending its cash runway into 2028 and funding key clinical milestones for its Alzheimer's drug candidate.

ProMIS Neurosciences Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the previously disclosed deficiency matter.

ProMIS Neurosciences Inc. announced a one-for-twenty-five reverse stock split to take effect on November 28, 2025, aimed at regaining compliance with Nasdaq's minimum bid price requirement.

ProMIS Neurosciences Inc. shareholders approved a special resolution for a share consolidation at a ratio between one-for-five and one-for-twenty-five, to be determined by the Board.

ProMIS Neurosciences announced its third quarter 2025 financial results and significant progress in its lead Alzheimer's disease clinical trial, PMN310.

ProMIS Neurosciences strengthens its Board of Directors with the appointment of Slanix Paul Alex, Pharm.D., a seasoned healthcare investment professional from Ally Bridge Group.

ProMIS Neurosciences Inc. has amended its employment agreement with Chief Scientific Officer Neil Cashman, updating his compensation and severance terms.

ProMIS Neurosciences' lead Alzheimer's therapeutic candidate, PMN310, has received unanimous DSMB approval to proceed to the third and final dose escalation cohort in its Phase 1b clinical trial, with no amyloid-related imaging abnormalities observed to date.

ProMIS Neurosciences Inc. has established an At The Market offering program to sell up to $17.99 million in common shares through H.C. Wainwright & Co., LLC.

ProMIS Neurosciences reports Q2 2025 financial results, highlights FDA Fast Track designation for PMN310 in Alzheimer's, and successful capital raise.

ProMIS Neurosciences Inc. announced a private placement offering of warrants, raising approximately $3.0 million, which combined with existing warrant exercises, totals $12.0 million in gross proceeds to fund clinical development of PMN310.

ProMIS Neurosciences Inc. announced the successful closing of a registered direct offering and a private placement, raising a total of $9.2 million to fund the clinical development of its lead therapeutic candidate, PMN310, and for general corporate expenses.

ProMIS Neurosciences Inc. announced that its lead Alzheimer's therapeutic candidate, PMN310, received FDA Fast Track Designation, while also mutually agreeing to terminate its At-The-Market offering program with BTIG, LLC.

ProMIS Neurosciences Inc. has been granted an additional 180-calendar day period by Nasdaq, until December 29, 2025, to regain compliance with the minimum $1.00 bid price requirement.

ProMIS Neurosciences Inc. announced that its stockholders approved the 2025 Stock Option and Incentive Plan, elected seven directors, and ratified Baker Tilly US, LLP as its independent auditor at the Annual Meeting held on June 12, 2025.

ProMIS Neurosciences reports Q1 2025 financial results and highlights progress in its Alzheimer's disease program, including the completion of the first cohort in the PRECISE-AD trial.

ProMIS Neurosciences reports full year 2024 financial results, highlighting clinical trial advancements and a strengthened financial position.

ProMIS Neurosciences announces the dosing of multiple patients in its Phase 1b PRECISE-AD clinical trial evaluating PMN310 for Alzheimer's disease.

Promis Neurosciences Inc. reports the departure of Chief Operating Officer Gavin T. Malenfant, effective February 14, 2025, and the termination of the COO position.

ProMIS Neurosciences has released an updated corporate presentation detailing the progress of its clinical and preclinical programs targeting neurodegenerative diseases, including Alzheimer's, ALS, and synucleinopathies.

ProMIS Neurosciences has commenced a Phase 1b clinical trial for its lead drug candidate, PMN310, targeting toxic oligomers in Alzheimer's disease.

Promis Neurosciences Inc. has received a notice from Nasdaq for failing to maintain a minimum share price of $1, placing the company at risk of delisting.

ProMIS Neurosciences announced positive results from its Phase 1a clinical trial for PMN310, showing it was well-tolerated and achieved target engagement levels, and secured a significant financing to advance its pipeline.

ProMIS Neurosciences shareholders approved a proposal for the potential issuance of common shares related to warrants from a private placement, and also approved an adjournment proposal, though it was not needed.

ProMIS Neurosciences has officially appointed Neil Warma as its President and CEO, effective August 1, 2024, and granted him significant stock options as part of his compensation package.

ProMIS Neurosciences announced positive topline data from its Phase 1a clinical trial for PMN310 and secured up to $122.7 million in private placement financing.

ProMIS Neurosciences has regained compliance with NASDAQ's minimum market value requirement after its stock price exceeded $35 million for ten consecutive days.